Use of a high infusion rate to prevent posterior dislocation of fluocinolone acetonide implant during surgical removal

Ocular Immunology and Inflammation

Volumn 19, Issue 3, 2011, Pages 214-215

  Wan, Wenjuan ^a,b   Stewart, Jay M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

dissociation; exchange; fluocinolone implant; infusion pressure; uveitis

Indexed keywords

FLUOCINOLONE ACETONIDE;

ADULT; ARTICLE; CADAVER; CASE REPORT; DEVICE REMOVAL; EYE EXAMINATION; FEMALE; HUMAN; IN VITRO STUDY; MULTIPLE SCLEROSIS; POSTERIOR DISOLOCATION; PROSTHESIS FAILURE; RISK ASSESSMENT; SARCOIDOSIS; SCLERA; UVEITIS; VISUAL ACUITY; VITRECTOMY;

ADULT; ANTI-INFLAMMATORY AGENTS; CADAVER; DEVICE REMOVAL; DRUG IMPLANTS; FEMALE; FLUOCINOLONE ACETONIDE; FOREIGN-BODY MIGRATION; HUMANS; INFUSIONS, INTRALESIONAL; PANUVEITIS; PRESSURE;

EID: 79957445352     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2011.553980     Document Type: Article

References (4)

1. Yeh S, Cebulla CM, Witherspoon SR, et al . Management of fluocinolone implant dissociation during implant exchange. Arch Ophthalmol. 2009; 127(9): 1218-1221
2. Taban M, Lowder CY, Kaiser PK. Outcome of fluocinolone acetonide implant (Retisert(Tm)) reimplantation for chronic noninfectious posterior uveitis. Retina. 2008; 28(9): 1280-1288
3. Jaffe GJ. Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis. Am J Ophthalmol. 2008(4); 145: 667-675
4. Retisert (fluocinolone acetonide intravitreal implant 059 mg) prescribing information, Bausch & Lomb; 2009